Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- FPMAJ to Introduce Bar Code System Starting from Bio-derived Products
December 29, 2003
- WORLD NEWS IN BRIEF
December 29, 2003
- Quintiles' CSO Business Growing Rapidly
December 29, 2003
- The Value of New Medicines
December 29, 2003
- BUSINESS NEWS IN BRIEF
December 29, 2003
- MEETING
December 29, 2003
- Medical Fees Remain Unchanged
December 29, 2003
- Meet the Leaders (28)
December 29, 2003
- 5 Ingredients/9 Products Included in NHI List
December 29, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 29, 2003
- Proposed Basic Policy for FY2004 Medical Fee Revision Approved
December 29, 2003
- New Year's Message
December 29, 2003
- BULLETIN
December 29, 2003
- Looking at the Year Ahead
December 29, 2003
- REGULATORY NEWS IN BRIEF
December 29, 2003
- ＜New Year's Messages＞
December 29, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 29, 2003
- New Year's Greetings
December 29, 2003
- NEW PRODUCTS
December 29, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 22, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…